
US investment banking company and financial analyst Jefferies views data from US pharmaceutical company Eli Lilly's recent studies with tirzepatide up against Danish firm Novo Nordisk's semaglutide as highly convincing. In-house analyst Peter Welford thinks Novo Nordisk's salespeople will have a hard time contesting tirzepatide's superior effect, since the new data comes from a direct comparison study, known as a head-to-head.
Thus, he thinks Novo Nordisk should be watchful of Eli Lilly's attempts to steal market shares in the GLP-1 segment with the new product, according to Danish newspaper Børsen.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app